Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shailender Bhatia

Showing results (101-110 of 123) with videos related to

Pageof 13
Sort By:
Cancer Cell|April 12, 2022
Neoantigen-specific CD4<sup>+</sup> T cells in human melanoma have diverse differentiation states and correlate with CD8<sup>+</sup> T cell, macrophage, and B cell functionJoshua R Veatch, Sylvia M Lee, Carolyn Shasha, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyYana G Najjar, Kristina Navrazhina, Fei Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 TrialSuzanne L Topalian, Shailender Bhatia, Asim Amin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Journal of the American Academy of Dermatology|October 12, 2025
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient managementTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic ImplicationsTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Cell|October 17, 2017
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabNadeem Riaz, Jonathan J Havel, Vladimir Makarov, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal for Immunotherapy of Cancer|July 25, 2025
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumorsMohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, et al.
Pageof 13

Showing results (101-110 of 123) with videos related to

Sort By:
Pageof 13
Cancer Cell|April 12, 2022
Neoantigen-specific CD4<sup>+</sup> T cells in human melanoma have diverse differentiation states and correlate with CD8<sup>+</sup> T cell, macrophage, and B cell functionJoshua R Veatch, Sylvia M Lee, Carolyn Shasha, et al.
Journal for Immunotherapy of Cancer|June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyYana G Najjar, Kristina Navrazhina, Fei Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 TrialSuzanne L Topalian, Shailender Bhatia, Asim Amin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaAlain P Algazi, Christopher G Twitty, Katy K Tsai, et al.
Journal of the American Academy of Dermatology|October 12, 2025
Circulating tumor DNA level is associated with time to clinical recurrence in Merkel cell carcinoma: Implications for patient managementTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2024
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic ImplicationsTomoko Akaike, Manisha Thakuria, Ann W Silk, et al.
Cell|October 17, 2017
Tumor and Microenvironment Evolution during Immunotherapy with NivolumabNadeem Riaz, Jonathan J Havel, Vladimir Makarov, et al.
The New England Journal of Medicine|June 5, 2012
Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer, Scott S Tykodi, Laura Q M Chow, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Journal for Immunotherapy of Cancer|July 25, 2025
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumorsMohammed M Milhem, Trisha M Wise-Draper, Sunandana Chandra, et al.
Pageof 13